Trial Profile
An observational study of anagrelide for the treatment of essential thrombocythemia in patients who have failed initial treatment with hydroxyuria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Anagrelide (Primary)
- Indications Thrombocytosis
- Focus Therapeutic Use
- 14 Dec 2015 New trial record